1
|
Forte M, D'Ambrosio L, Schiattarella GG, Salerno N, Perrone MA, Loffredo FS, Bertero E, Pilichou K, Manno G, Valenti V, Spadafora L, Bernardi M, Simeone B, Sarto G, Frati G, Perrino C, Sciarretta S. Mitophagy modulation for the treatment of cardiovascular diseases. Eur J Clin Invest 2024:e14199. [PMID: 38530070 DOI: 10.1111/eci.14199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 03/15/2024] [Accepted: 03/16/2024] [Indexed: 03/27/2024]
Abstract
BACKGROUND Defects of mitophagy, the selective form of autophagy for mitochondria, are commonly observed in several cardiovascular diseases and represent the main cause of mitochondrial dysfunction. For this reason, mitophagy has emerged as a novel and potential therapeutic target. METHODS In this review, we discuss current evidence about the biological significance of mitophagy in relevant preclinical models of cardiac and vascular diseases, such as heart failure, ischemia/reperfusion injury, metabolic cardiomyopathy and atherosclerosis. RESULTS Multiple studies have shown that cardiac and vascular mitophagy is an adaptive mechanism in response to stress, contributing to cardiovascular homeostasis. Mitophagy defects lead to cell death, ultimately impairing cardiac and vascular function, whereas restoration of mitophagy by specific compounds delays disease progression. CONCLUSIONS Despite previous efforts, the molecular mechanisms underlying mitophagy activation in response to stress are not fully characterized. A comprehensive understanding of different forms of mitophagy active in the cardiovascular system is extremely important for the development of new drugs targeting this process. Human studies evaluating mitophagy abnormalities in patients at high cardiovascular risk also represent a future challenge.
Collapse
Affiliation(s)
| | - Luca D'Ambrosio
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
| | - Gabriele G Schiattarella
- Max Rubner Center for Cardiovascular Metabolic Renal Research, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
| | - Nadia Salerno
- Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
| | - Marco Alfonso Perrone
- Division of Cardiology and CardioLab, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy
- Clinical Pathways and Epidemiology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
| | - Francesco S Loffredo
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples, Italy
| | - Edoardo Bertero
- Department of Internal Medicine, University of Genova, Genoa, Italy
- Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino-Italian IRCCS Cardiology Network, Genoa, Italy
| | - Kalliopi Pilichou
- Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Girolamo Manno
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy
| | - Valentina Valenti
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
- ICOT Istituto Marco Pasquali, Latina, Italy
| | | | - Marco Bernardi
- Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University, Rome, Italy
| | | | | | - Giacomo Frati
- IRCCS Neuromed, Pozzilli, Italy
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
| | - Cinzia Perrino
- Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy
| | - Sebastiano Sciarretta
- IRCCS Neuromed, Pozzilli, Italy
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
| |
Collapse
|
2
|
Mauriello A, Roma AS, Ascrizzi A, Molinari R, Loffredo FS, D’Andrea A, Russo V. Arrhythmogenic Left Ventricular Cardiomyopathy: From Diagnosis to Risk Management. J Clin Med 2024; 13:1835. [PMID: 38610600 PMCID: PMC11012337 DOI: 10.3390/jcm13071835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 03/13/2024] [Accepted: 03/16/2024] [Indexed: 04/14/2024] Open
Abstract
PURPOSE OF REVIEW Left ventricular arrhythmogenic cardiomyopathy (ALVC) is a rare and poorly characterized cardiomyopathy that has recently been reclassified in the group of non-dilated left ventricular cardiomyopathies. This review aims to summarize the background, diagnosis, and sudden cardiac death risk in patients presenting this cardiomyopathy. RECENT FINDINGS Although there is currently a lack of data on this condition, arrhythmogenic left ventricular dysplasia can be considered a specific disease of the left ventricle (LV). We have collected the latest evidence about the management and the risks associated with this cardiomyopathy. SUMMARY Left ventricular arrhythmogenic cardiomyopathy is still poorly characterized. ALVC is characterized by fibrofatty replacement in the left ventricular myocardium, with variable phenotypic expression. Diagnosis is based on a multiparametric approach, including cardiac magnetic resonance (CMR) and genetic testing, and is important for sudden cardiac death (SCD) risk stratification and management. Recent guidelines have improved the management of left ventricular arrhythmogenic cardiomyopathy. Further studies are necessary to improve knowledge of this cardiomyopathy.
Collapse
Affiliation(s)
- Alfredo Mauriello
- Cardiology Unit, Department of Medical Translational Science, University of Campania “Luigi Vanvitelli”—“V. Monaldi” Hospital, 80126 Naples, Italy; (A.S.R.); (A.A.); (R.M.); (F.S.L.); (A.D.); (V.R.)
- Unit of Cardiology, “Umberto I” Hospital, 84014 Nocera Inferiore, Italy
| | - Anna Selvaggia Roma
- Cardiology Unit, Department of Medical Translational Science, University of Campania “Luigi Vanvitelli”—“V. Monaldi” Hospital, 80126 Naples, Italy; (A.S.R.); (A.A.); (R.M.); (F.S.L.); (A.D.); (V.R.)
| | - Antonia Ascrizzi
- Cardiology Unit, Department of Medical Translational Science, University of Campania “Luigi Vanvitelli”—“V. Monaldi” Hospital, 80126 Naples, Italy; (A.S.R.); (A.A.); (R.M.); (F.S.L.); (A.D.); (V.R.)
| | - Riccardo Molinari
- Cardiology Unit, Department of Medical Translational Science, University of Campania “Luigi Vanvitelli”—“V. Monaldi” Hospital, 80126 Naples, Italy; (A.S.R.); (A.A.); (R.M.); (F.S.L.); (A.D.); (V.R.)
| | - Francesco S. Loffredo
- Cardiology Unit, Department of Medical Translational Science, University of Campania “Luigi Vanvitelli”—“V. Monaldi” Hospital, 80126 Naples, Italy; (A.S.R.); (A.A.); (R.M.); (F.S.L.); (A.D.); (V.R.)
| | - Antonello D’Andrea
- Cardiology Unit, Department of Medical Translational Science, University of Campania “Luigi Vanvitelli”—“V. Monaldi” Hospital, 80126 Naples, Italy; (A.S.R.); (A.A.); (R.M.); (F.S.L.); (A.D.); (V.R.)
- Unit of Cardiology, “Umberto I” Hospital, 84014 Nocera Inferiore, Italy
| | - Vincenzo Russo
- Cardiology Unit, Department of Medical Translational Science, University of Campania “Luigi Vanvitelli”—“V. Monaldi” Hospital, 80126 Naples, Italy; (A.S.R.); (A.A.); (R.M.); (F.S.L.); (A.D.); (V.R.)
| |
Collapse
|
3
|
Natale F, Raucci G, Molinari R, Alfieri R, D’Arienzo D, Pezzullo E, Loffredo FS, Golino P, Cimmino G. Catch the Cath or Not? A Hamletic Dilemma after 10 Years. J Cardiovasc Echogr 2023; 33:189-191. [PMID: 38486691 PMCID: PMC10936701 DOI: 10.4103/jcecho.jcecho_68_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 12/18/2023] [Accepted: 12/29/2023] [Indexed: 03/17/2024] Open
Abstract
In the last few years, a tremendous advancement has been made in the therapeutical management of several diseases with an increasing need for parental drug administration. To avoid repeated venous insertions and the patient's anxiety related to these procedures, it is now common practice to insert a catheter to leave it in place for a longer time. However, these procedures may generate some complications, such as failure of insertion, embolization, and infection. Different noninvasive techniques have been proposed and used for the retrieval of lost or misplaced foreign objects. Here, we presented a case of the lost fragmented catheter in a young female who underwent a central venous catheter insertion 10 years ago, incidentally detected during an echocardiographic examination. Here, we presented a case of a lost fragmented catheter in a young female who underwent a central venous catheter insertion 10 years before.
Collapse
Affiliation(s)
- Francesco Natale
- Department of Cardiology, Vanvitelli Cardiology Unit, Monaldi Hospital, Piazza Miraglia, Naples, Italy
| | - Giuseppe Raucci
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, Piazza Miraglia, Naples, Italy
| | - Riccardo Molinari
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, Piazza Miraglia, Naples, Italy
| | - Roberta Alfieri
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, Piazza Miraglia, Naples, Italy
| | - Diego D’Arienzo
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, Piazza Miraglia, Naples, Italy
| | - Enrica Pezzullo
- Department of Cardiology, Vanvitelli Cardiology Unit, Monaldi Hospital, Piazza Miraglia, Naples, Italy
| | - Francesco S Loffredo
- Department of Cardiology, Vanvitelli Cardiology Unit, Monaldi Hospital, Piazza Miraglia, Naples, Italy
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, Piazza Miraglia, Naples, Italy
| | - Paolo Golino
- Department of Cardiology, Vanvitelli Cardiology Unit, Monaldi Hospital, Piazza Miraglia, Naples, Italy
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, Piazza Miraglia, Naples, Italy
| | - Giovanni Cimmino
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, Piazza Miraglia, Naples, Italy
- Department of Internal Medicine, Gerontology and Neurology, Cardiology Unit, Azienda Ospedaliera Universitaria “Luigi Vanvitelli”, Piazza Miraglia, Naples, Italy
| |
Collapse
|
4
|
Cimmino G, Natale F, Alfieri R, Cante L, Covino S, Franzese R, Limatola M, Marotta L, Molinari R, Mollo N, Loffredo FS, Golino P. Non-Conventional Risk Factors: "Fact" or "Fake" in Cardiovascular Disease Prevention? Biomedicines 2023; 11:2353. [PMID: 37760794 PMCID: PMC10525401 DOI: 10.3390/biomedicines11092353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 08/18/2023] [Accepted: 08/21/2023] [Indexed: 09/29/2023] Open
Abstract
Cardiovascular diseases (CVDs), such as arterial hypertension, myocardial infarction, stroke, heart failure, atrial fibrillation, etc., still represent the main cause of morbidity and mortality worldwide. They significantly modify the patients' quality of life with a tremendous economic impact. It is well established that cardiovascular risk factors increase the probability of fatal and non-fatal cardiac events. These risk factors are classified into modifiable (smoking, arterial hypertension, hypercholesterolemia, low HDL cholesterol, diabetes, excessive alcohol consumption, high-fat and high-calorie diet, reduced physical activity) and non-modifiable (sex, age, family history, of previous cardiovascular disease). Hence, CVD prevention is based on early identification and management of modifiable risk factors whose impact on the CV outcome is now performed by the use of CV risk assessment models, such as the Framingham Risk Score, Pooled Cohort Equations, or the SCORE2. However, in recent years, emerging, non-traditional factors (metabolic and non-metabolic) seem to significantly affect this assessment. In this article, we aim at defining these emerging factors and describe the potential mechanisms by which they might contribute to the development of CVD.
Collapse
Affiliation(s)
- Giovanni Cimmino
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Naples, Italy
| | - Francesco Natale
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Roberta Alfieri
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Luigi Cante
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Simona Covino
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Rosa Franzese
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Mirella Limatola
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Luigi Marotta
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Riccardo Molinari
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Noemi Mollo
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Francesco S Loffredo
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| | - Paolo Golino
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy (F.S.L.)
- Vanvitelli Cardiology Unit, Monaldi Hospital, 80131 Naples, Italy
| |
Collapse
|
5
|
Catapano D, Tontodonato M, D'Elia S, Pezzullo E, Ciaramella F, Vettori S, Bussani R, Ciucci G, Collesi C, Sinagra G, Golino P, Loffredo FS. Fulminant Myocarditis Unmasking Adult-Onset Still's Disease and Desmoplakin Truncation. Circ Cardiovasc Imaging 2023; 16:e015001. [PMID: 37283033 DOI: 10.1161/circimaging.122.015001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- Dario Catapano
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (D.C., M.T., S.D., E.P., F.C., P.G., F.S.L.)
| | - Marco Tontodonato
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (D.C., M.T., S.D., E.P., F.C., P.G., F.S.L.)
| | - Saverio D'Elia
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (D.C., M.T., S.D., E.P., F.C., P.G., F.S.L.)
| | - Enrica Pezzullo
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (D.C., M.T., S.D., E.P., F.C., P.G., F.S.L.)
| | - Francesco Ciaramella
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (D.C., M.T., S.D., E.P., F.C., P.G., F.S.L.)
| | | | - Rossana Bussani
- Pathology Department, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste, Italy (R.B.)
| | - Giulio Ciucci
- International Center for Genetic Engineering and Biotechnology, Trieste, Italy (G.C., C.C.)
| | - Chiara Collesi
- International Center for Genetic Engineering and Biotechnology, Trieste, Italy (G.C., C.C.)
- Department of Medicine, Surgery and Health Sciences (C.C.), University of Trieste, Italy
| | - Gianfranco Sinagra
- Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) (G.S.), University of Trieste, Italy
| | - Paolo Golino
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (D.C., M.T., S.D., E.P., F.C., P.G., F.S.L.)
| | - Francesco S Loffredo
- Division of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (D.C., M.T., S.D., E.P., F.C., P.G., F.S.L.)
| |
Collapse
|
6
|
Cimmino G, Loffredo FS, De Rosa G, Cirillo P. Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence. Int J Mol Sci 2023; 24:ijms24032483. [PMID: 36768804 PMCID: PMC9917272 DOI: 10.3390/ijms24032483] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 01/23/2023] [Accepted: 01/25/2023] [Indexed: 01/31/2023] Open
Abstract
Several lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the use of anti-inflammatory agents might be extremely useful to improve cardiovascular outcome. Recently, increasing attention has been reserved to one of the oldest plant-derived drugs still in use in clinical practice, colchicine that has been used as drug to treat inflammatory diseases such gout or Mediterranean fever. To date, current guidelines of the European Society of Cardiology have included colchicine as first line choice for treatment of acute and recurrent pericarditis. Moreover, several studies have investigated its role in the clinical scenarios of cardiovascular disease including chronic and acute coronary syndromes with promising results. In this review, starting from a description of the mechanism(s) involved behind its anti-inflammatory effects, we give an overview on its potential effects in atherothrombosis and finally present an updated overview of clinical evidence on the role of this drug in cardiovascular disease.
Collapse
Affiliation(s)
- Giovanni Cimmino
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy
- Correspondence: ; Tel.: +39-081-7064239
| | - Francesco S. Loffredo
- Department of Advanced Biomedical Sciences, Section of Cardiology, University of Naples “Federico II”, 80131 Naples, Italy
| | - Gennaro De Rosa
- Department of Advanced Biomedical Sciences, Section of Cardiology, University of Naples “Federico II”, 80131 Naples, Italy
| | - Plinio Cirillo
- Department of Advanced Biomedical Sciences, Section of Cardiology, University of Naples “Federico II”, 80131 Naples, Italy
| |
Collapse
|
7
|
Ciucci G, Rahhali K, Cimmino G, Natale F, Golino P, Sinagra G, Collesi C, Loffredo FS. Engineered heart tissue maturation inhibits cardiomyocyte proliferative response to cryoinjury. J Tissue Eng 2023; 14:20417314231190147. [PMID: 37842206 PMCID: PMC10571691 DOI: 10.1177/20417314231190147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 07/11/2023] [Indexed: 10/17/2023] Open
Abstract
The cellular and molecular mechanisms that are responsible for the poor regenerative capacity of the adult heart after myocardial infarction (MI) are still unclear and their understanding is crucial to develop novel regenerative therapies. Considering the lack of reliable in vitro tissue-like models to evaluate the molecular mechanisms of cardiac regeneration, we used cryoinjury on rat Engineered Heart Tissues (rEHTs) as a new model which recapitulates in part the in vivo response after myocardial injury of neonatal and adult heart. When we subjected to cryoinjury immature and mature rEHTs, we observed a significant increase in cardiomyocyte (CM) DNA synthesis when compared to the controls. As expected, the number of mitotic CMs significantly increases in immature rEHTs when compared to mature rEHTs, suggesting that the extent of CM maturation plays a crucial role in their proliferative response after cryoinjury. Moreover, we show that cryoinjury induces a temporary activation of fibroblast response in mature EHTs, similar to the early response after MI, that is however incomplete in immature EHTs. Our results support the hypothesis that the endogenous maturation program in cardiac myocytes plays a major role in determining the proliferative response to injury. Therefore, we propose rEHTs as a robust, novel tool to in vitro investigate critical aspects of cardiac regeneration in a tissue-like asset free from confounding factors in response to injury, such as the immune system response or circulating inflammatory cytokines.
Collapse
Affiliation(s)
- Giulio Ciucci
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Friuli-Venezia Giulia, Italy
| | - Karim Rahhali
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Friuli-Venezia Giulia, Italy
- Molecular Medicine, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
| | - Giovanni Cimmino
- Department of Translational Medical Sciences, Division of Cardiology, University of Campania “L. Vanvitelli,” Naples, Italy
| | - Francesco Natale
- Department of Translational Medical Sciences, Division of Cardiology, University of Campania “L. Vanvitelli,” Naples, Italy
| | - Paolo Golino
- Department of Translational Medical Sciences, Division of Cardiology, University of Campania “L. Vanvitelli,” Naples, Italy
| | - Gianfranco Sinagra
- Department of Medicine, Surgery and Health Sciences, Azienda Sanitaria-Universitaria Integrata Trieste “ASUITS,” University of Trieste, Trieste, Italy
| | - Chiara Collesi
- Department of Medicine, Surgery and Health Sciences, Azienda Sanitaria-Universitaria Integrata Trieste “ASUITS,” University of Trieste, Trieste, Italy
- Molecular Medicine, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
| | - Francesco S Loffredo
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Friuli-Venezia Giulia, Italy
- Department of Translational Medical Sciences, Division of Cardiology, University of Campania “L. Vanvitelli,” Naples, Italy
| |
Collapse
|
8
|
Natale F, Loffredo FS, Salerno G, Molinari R, Pezzullo E, Golino P, Cimmino G. Safety of Transesophageal Echocardiogram in Anticoagulated Patients. J Cardiovasc Echogr 2023; 33:59-60. [PMID: 37426722 PMCID: PMC10328132 DOI: 10.4103/jcecho.jcecho_72_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 01/07/2023] [Accepted: 01/09/2023] [Indexed: 07/11/2023] Open
Affiliation(s)
- Francesco Natale
- Department of Cardiology, AOU Monaldi, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Francesco S Loffredo
- Department of Cardiology, AOU Monaldi, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Gemma Salerno
- Department of Cardiology, AOU Monaldi, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Riccardo Molinari
- Department of Cardiology, AOU Monaldi, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Enrica Pezzullo
- Department of Cardiology, AOU Monaldi, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Paolo Golino
- Department of Cardiology, AOU Monaldi, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Giovanni Cimmino
- Department of Cardiology, AOU Monaldi, University of Campania Luigi Vanvitelli, Naples, Italy
| |
Collapse
|
9
|
Natale F, Capasso R, Casalino A, Crescenzi C, Sangiuolo P, Golino P, Loffredo FS, Cimmino G. Peripheral Artery Disease and Abdominal Aortic Aneurysm: The Forgotten Diseases in COVID-19 Pandemic. Results from an Observational Study on Real-World Management. ACTA ACUST UNITED AC 2021; 57:medicina57070672. [PMID: 34209552 PMCID: PMC8307785 DOI: 10.3390/medicina57070672] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 06/11/2021] [Accepted: 06/25/2021] [Indexed: 12/24/2022]
Abstract
Background and Objectives: It is well established that patients with peripheral artery disease (PAD) as well abdominal aortic aneurysm (AAA) have an increased cardiovascular (CV) mortality. Despite this higher risk, PAD and AAA patients are often suboptimality treated. This study assessed the CV profile of PAD and AAA patients, quantifying the survival benefits of target-based risk-factors modification even in light of the COVID-19 pandemic. Materials and Methods: PAD and AAA patients admitted for any reason to the Vascular Unit from January 2019 to February 2020 were retrospectively analyzed. Biochemical and CV profiles as well as ongoing medical therapies were recorded. Benefits of CV risk-factors control were estimated using the SMART-REACH model. A follow-up visit during the year 2020 was scheduled. Results: A total of 669 patients were included. Of these, 190 showed AAA and 479 PAD at any stage. Only 54% of PAD and 41% of AAA patients were on lipid-lowering drugs with non-optimal low-density lipoprotein (LDL) levels for most of them. A better control of all modifiable CV risk-factors based on the current guidelines would offer an absolute risk reduction of the mean 10-year CV risk by 9% in PAD and 14% in AAA. Unfortunately, the follow-up visit was lost because of COVID-19 limitations. Conclusions: Lipid profiles of PAD and AAA patients were far from guideline-based targets, and medical management was suboptimal. In our center, the COVID-19 pandemic impacted on the strict surveillance required in these very high-risk patients. The achievement of guideline-based therapeutic targets would definitively confer additional significant benefits in reducing the CV risk in these patients.
Collapse
Affiliation(s)
- Francesco Natale
- Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy; (P.G.); (F.S.L.)
- Correspondence: ; Tel.:+39-0817064239
| | - Raffaele Capasso
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy; (R.C.); (G.C.)
| | - Alfonso Casalino
- Vascular Surgery Unit, Monaldi Hospital, 80131 Naples, Italy; (A.C.); (C.C.); (P.S.)
| | - Clotilde Crescenzi
- Vascular Surgery Unit, Monaldi Hospital, 80131 Naples, Italy; (A.C.); (C.C.); (P.S.)
| | - Paolo Sangiuolo
- Vascular Surgery Unit, Monaldi Hospital, 80131 Naples, Italy; (A.C.); (C.C.); (P.S.)
| | - Paolo Golino
- Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy; (P.G.); (F.S.L.)
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy; (R.C.); (G.C.)
| | - Francesco S. Loffredo
- Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy; (P.G.); (F.S.L.)
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy; (R.C.); (G.C.)
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy
| | - Giovanni Cimmino
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy; (R.C.); (G.C.)
- Cardiology Unit, Policlinico Vanvitelli, 80138 Naples, Italy
| |
Collapse
|
10
|
Cannatà A, Gentile P, Paldino A, Nuzzi V, Camparini L, Ciucci G, Manca P, Artico J, Dal Ferro M, Marcon G, Tettamanti M, Merlo M, Sinagra G, Loffredo FS. Echocardiographic evaluation of centenarians in Trieste. J Cardiovasc Med (Hagerstown) 2020; 21:556-561. [PMID: 32520856 DOI: 10.2459/jcm.0000000000000984] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Population aging has increased together with the need for cardiovascular care. Understanding the relevance of cardiovascular conditions in the very old is crucial to developing a specific and rationale therapeutic approach. Centenarians can be considered a model of successful aging, although the impact of cardiovascular disease in this population is still unclear. AIM To evaluate the cardiovascular health status of a subset of centenarians enrolled in the Centenari a Trieste study and living in the province of Trieste to describe the prevalence of cardiovascular conditions among them. METHODS The current study included 20 individuals born before 1919 and living in the province of Trieste as of 1 May 2019. All centenarians were able to give consent and were subjected to an in-home complete clinical assessment focused on cardiovascular conditions, ECG and echocardiography. RESULTS The majority of centenarians were women (85%) and were not taking any chronic cardiovascular medication (55%). No centenarians had a history of ischemic heart disease while about one-third had signs suggestive of heart failure at examination (20%). Atrial fibrillation was present in 20% of individuals and conduction disorders were uncommon. Although the majority of individuals had a preserved left ventricular function, diastolic function was abnormal in 80% of enrolled centenarians that, however, was mild in 73% of cases. CONCLUSION This is the second study to perform in-home echocardiography in centenarians and the first to characterize the cardiovascular status of centenarians living in Trieste. The majority of centenarians had asymptomatic diastolic dysfunction and were naïve from cardiovascular therapy. The recruitment of new individuals from the Trieste area is continuing to perform analyses on clinical, genetic and environmental factors that may predict greater longevity in this geographical context and unveil mechanisms that regulate cardiac aging associated with increased lifespan.
Collapse
Affiliation(s)
- Antonio Cannatà
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste.,Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.,Department of Cardiovascular Sciences - Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - Piero Gentile
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Alessia Paldino
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Vincenzo Nuzzi
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Luca Camparini
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Giulio Ciucci
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Paolo Manca
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Jessica Artico
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Matteo Dal Ferro
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Gabriella Marcon
- Department of Medicine, Surgery and Health Sciences, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste, Trieste.,Department of Medicine, University of Udine, Udine
| | - Mauro Tettamanti
- Laboratory of Geriatric Neuropsychiatry, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - Marco Merlo
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Gianfranco Sinagra
- Cardiovascular Department, Azienda Sanitaria-Universitaria Integrata Trieste 'ASUITS', University of Trieste
| | - Francesco S Loffredo
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.,Division of Cardiology, Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy
| |
Collapse
|
11
|
Camparini L, Kollipara L, Sinagra G, Loffredo FS, Sickmann A, Shevchuk O. Targeted Approach to Distinguish and Determine Absolute Levels of GDF8 and GDF11 in Mouse Serum. Proteomics 2020; 20:e1900104. [PMID: 32104967 DOI: 10.1002/pmic.201900104] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 01/31/2020] [Indexed: 12/14/2022]
Abstract
Growth differentiation factor 11 (GDF11) is a TGF-β superfamily circulating factor that regulates cardiomyocyte size in rodents, sharing 90% amino acid sequence identity in the active domains with myostatin (GDF8)-the major determinant of skeletal muscle mass. Conflicting data on age-related changes in circulating levels have been reported mainly due to the lack of specific detection methods. More recently, liquid chromatography tandem mass spectrometry (LC-MS/MS) based assay showed that the circulating levels of GDF11 do not change significantly throughout human lifespan, but GDF8 levels decrease with aging in men. Here a novel detection method is demonstrated based on parallel reaction monitoring LC-MS/MS assay combined with immunoprecipitation to reliably distinguish GDF11 and GDF8 as well as determine their endogenous levels in mouse serum. The data indicate that both GDF11 and GDF8 circulating levels significantly decline with aging in female mice.
Collapse
Affiliation(s)
- Luca Camparini
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149, Trieste, Trieste, Italy
| | - Laxmikanth Kollipara
- Leibniz Institut für Analytische Wissenschaften-ISAS-e.V., Bunsen-Kirchhoff-Straße 11
- 44139 Dortmund, Germany, Dortmund, Germany
| | - Gianfranco Sinagra
- Division of Cardiology, Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Via Slataper, 9 - 34134, Trieste, Trieste, Italy
| | - Francesco S Loffredo
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149, Trieste, Trieste, Italy.,Division of Cardiology, Department of Translational Medical Sciences, University of Campania, Via Leonardo Bianchi - 80131, Napoli, Napoli, Italy
| | - Albert Sickmann
- Leibniz Institut für Analytische Wissenschaften-ISAS-e.V., Bunsen-Kirchhoff-Straße 11
- 44139 Dortmund, Germany, Dortmund, Germany
| | - Olga Shevchuk
- Leibniz Institut für Analytische Wissenschaften-ISAS-e.V., Bunsen-Kirchhoff-Straße 11
- 44139 Dortmund, Germany, Dortmund, Germany
| |
Collapse
|
12
|
Camparini L, Ciacci L, Sorrentino S, Ciucci G, Cannata A, Sinagra G, Loffredo FS. P1629Crispr/Cas9 to elucidate cardiac specific effects of Gdf11. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Heart failure with preserved ejection fraction (HFpEF) is a prevalent clinical condition in the aging population. HFpEF lacks specific therapies with a significant impact on survival, different therapeutic approaches have indeed failed, indicating a specific need in understanding the pathophysiology of the disease. Cardiac hypertrophy is one of the main features of HFpEF that contributes to impair diastolic function. Reducing ventricular stiffness associated with cardiomyocyte hypertrophy may indeed result in improved diastolic filling. Growth differentiation factor 11 (Gdf11), a TGF-β family factor, has been identified as a circulating factor able to reduce cardiac hypertrophy.
Purpose
Similar to myostatin (Gdf8), Gdf11 promotes the activation of atrophy pathways that induce ubiquitination of sarcomeric proteins. Gdf11 and Gdf8 activate both type I and II Tgf-β receptors, specifically by interacting with Acvr2a and Acvr2b (type II) and Alk 4/5/7 (type I), they activate Smad 3/4 pathway. Our data indicate a specific and more potent effect of Gdf11 in reducing cardiomyocytes size that is not recapitulated by Gdf8. Understanding the specific effect of Gdf11 on cardiomyocytes is crucial to develop therapeutic strategies to target the hypertrophic phenotype.
Methods
To investigate the effects of specific type I receptor KO on Smad signaling cascade we performed our preliminary experiment on HL-1 cells, a cardiac muscle cell line carrying a doxycycline inducible Cas9 transgene. Cell sensitivity of HL-1 to Gdf11 and Gdf8 was tested by performing a dose-response curve using a luciferase reporter for Smad 3/4 pathway activation (CAGA12). Selective Tgf-β type I receptor KO was induced using, for each receptor, two sgRNAs that have been designed to cleave the receptor coding sequence creating INDEL mutations and disrupt proper translation of the protein and confirmed by western blotting. Smad 3/4 activity was measured using a CAGA12-luciferase assay on HL-1-Cas9 transduced cells.
Results
Our data in HL-1 cells confirm a more potent effect of Gdf11 in activating Smad 3/4 pathway when compared to Gdf8 (Fig. 1A). Selective Alk4 and Alk5 KO induced a similar reduction in Smad 3/4 activation for both Gdf11 and Gdf8. Interestingly, Alk7 KO significantly reduced Gdf11 signaling that was not recapitulated when using Gdf8, suggesting that Alk7 receptor is crucial for Gdf11-dependent Smad 3/4 activation in HL-1 cells (Fig. 1B).
Figure 1
Conclusions
Our preliminary results indicate that part of Gdf11 cardiac specificity when compared to Gdf8 may reside in the usage of Alk7 for signaling. Alk7 has proposed as a protective factor for pathological cardiac hypertrophy by negatively regulating Mek-Erk1/2 signalling. Our results are now under investigation in vitro using mouse neonatal cardiomyocytes expressing Cas-9 and in vivo using cardiac-specific-Cas9-expressing C57 transgenic mice, in resting condition and after induction of pathological hypertrophy.
Collapse
Affiliation(s)
- L Camparini
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Molecular Cardiology, Trieste, Italy
| | - L Ciacci
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Molecular Cardiology, Trieste, Italy
| | - S Sorrentino
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Molecular Cardiology, Trieste, Italy
| | - G Ciucci
- International Centre for Genetic Engineering and Biotechnology (ICGEB), Molecular Cardiology, Trieste, Italy
| | - A Cannata
- University of Trieste, Department of Medical Sciences, Division of Cardiology, Trieste, Italy
| | - G Sinagra
- University of Trieste, Department of Medical Sciences, Division of Cardiology, Trieste, Italy
| | - F S Loffredo
- Second University of Naples, Department of Translational Medical Sciences, Division of Cardiology, Naples, Italy
| |
Collapse
|
13
|
Cimmino G, Loffredo FS, Morello A, D'Elia S, De Palma R, Cirillo P, Golino P. Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque. Curr Cardiol Rev 2017; 13:110-117. [PMID: 27758696 PMCID: PMC5452145 DOI: 10.2174/1573403x12666161014093812] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 09/24/2016] [Accepted: 10/06/2016] [Indexed: 12/21/2022] Open
Abstract
In the last twenty years, our comprehension of the molecular mechanisms involved in the formation, progression and complication of atherosclerotic plaque has advanced significantly and the main role of inflammation and immunity in this phenomenon is now largely accepted. Accumulating evidence highlight the crucial role of different inflammatory and immune cells, such as monocytes and T-lymphocytes, in the pathophysiology of atherosclerotic lesion, particularly in contributing to its com-plications, such as rupture or ulceration. According to the new terminology, “vulnerable plaque” identi-fies an inflamed atherosclerotic lesion that is particularly prone to rupture. Once disrupted, prothrom-botic material is exposed to the flowing blood, thus activating coagulation cascade and platelet aggrega-tion, ultimately leading to acute thrombus formation within the coronary vessel. To date this is the key event underlying the clinical manifestations of acute coronary syndromes (ACS). The degree of vessel occlusion (complete vs. incomplete) and the time of blood flow cessation will define the severity of clinical picture. This phenomenon seems to be the final effect of a complex inter-action between different local and systemic factors, involving the degree of inflammation, type of cells infiltration and the rheological characteristics of blood flow at the site of plaque rupture, thrombogenic substrates within the atherosclerotic lesion and different soluble mediators, already present or acutely released in the circulating blood. This article will review currently available data on the pathophysiology of ACS, emphasizing the immunological and inflammatory aspects of vulnerable plaque. We may pos-tulate that intraplaque antigens and local microenvironment will define the immune-inflammatory re-sponse and cells phenotype, thus determining the severity of clinical manifestations.
Collapse
Affiliation(s)
- Giovanni Cimmino
- Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, Second University of Naples, Naples, Italy
| | - Francesco S Loffredo
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Alberto Morello
- Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, Second University of Naples, Naples, Italy
| | - Saverio D'Elia
- Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, Second University of Naples, Naples, Italy
| | - Raffaele De Palma
- Department of Clinical and Experimental Medicine, Section of Immunology, Second University of Naples, Naples, Italy
| | - Plinio Cirillo
- Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy
| | - Paolo Golino
- Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, Second University of Naples, Naples, Italy
| |
Collapse
|
14
|
Cannatà A, Marcon G, Cimmino G, Camparini L, Ciucci G, Sinagra G, Loffredo FS. Role of circulating factors in cardiac aging. J Thorac Dis 2017; 9:S17-S29. [PMID: 28446965 PMCID: PMC5383555 DOI: 10.21037/jtd.2017.03.95] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Accepted: 01/31/2017] [Indexed: 12/11/2022]
Abstract
Worldwide increase in life expectancy is a major contributor to the epidemic of chronic degenerative diseases. Aging, indeed, simultaneously affects multiple organ systems, and it has been hypothesized that systemic alterations in regulators of tissue physiology may regulate this process. Cardiac aging itself is a major risk factor for cardiovascular diseases and, because of the intimate relationship with the brain, may contribute to increase the risk of neurodegenerative disorders. Blood-borne factors may play a major role in this complex and still elusive process. A number of studies, mainly based on the revival of parabiosis, a surgical technique very popular during the 70s of the 20th century to study the effect of a shared circulation in two animals, have indeed shown the potential that humoral factors can control the aging process in different tissues. In this article we review the role of circulating factors in cardiovascular aging. A better understanding of these mechanisms may provide new insights in the aging process and provide novel therapeutic opportunities for chronic age-related disorders.
Collapse
Affiliation(s)
- Antonio Cannatà
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
- Cardiovascular Department, Azienda Sanitaria Universitaria Integrata and University of Trieste, Trieste, Italy
| | - Gabriella Marcon
- DAMA- University of Udine, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Italy
| | - Giovanni Cimmino
- Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, Second University of Naples, Naples, Italy
| | - Luca Camparini
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Giulio Ciucci
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | - Gianfranco Sinagra
- Cardiovascular Department, Azienda Sanitaria Universitaria Integrata and University of Trieste, Trieste, Italy
| | - Francesco S. Loffredo
- Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
- Cardiovascular Department, Azienda Sanitaria Universitaria Integrata and University of Trieste, Trieste, Italy
| |
Collapse
|
15
|
Cannatà A, Camparini L, Sinagra G, Giacca M, Loffredo FS. Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation. Cardiovasc Res 2016; 111:142-53. [DOI: 10.1093/cvr/cvw106] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Accepted: 05/10/2016] [Indexed: 01/07/2023] Open
|
16
|
|
17
|
Poggioli T, Vujic A, Yang P, Macias-Trevino C, Uygur A, Loffredo FS, Pancoast JR, Cho M, Goldstein J, Tandias RM, Gonzalez E, Walker RG, Thompson TB, Wagers AJ, Fong YW, Lee RT. Circulating Growth Differentiation Factor 11/8 Levels Decline With Age. Circ Res 2015; 118:29-37. [PMID: 26489925 DOI: 10.1161/circresaha.115.307521] [Citation(s) in RCA: 151] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 10/21/2015] [Indexed: 12/29/2022]
Abstract
RATIONALE Growth differentiation factor 11 (GDF11) and GDF8 are members of the transforming growth factor-β superfamily sharing 89% protein sequence homology. We have previously shown that circulating GDF11 levels decrease with age in mice. However, a recent study by Egerman et al reported that GDF11/8 levels increase with age in mouse serum. OBJECTIVE Here, we clarify the direction of change of circulating GDF11/8 levels with age and investigate the effects of GDF11 administration on the murine heart. METHODS AND RESULTS We validated our previous finding that circulating levels of GDF11/8 decline with age in mice, rats, horses, and sheep. Furthermore, we showed by Western analysis that the apparent age-dependent increase in GDF11 levels, as reported by Egerman et al, is attributable to cross-reactivity of the anti-GDF11 antibody with immunoglobulin, which is known to increase with age. GDF11 administration in mice rapidly activated SMAD2 and SMAD3 signaling in myocardium in vivo and decreased cardiac mass in both young (2-month-old) and old (22-month-old) mice in a dose-dependent manner after only 9 days. CONCLUSIONS Our study confirms an age-dependent decline in serum GDF11/8 levels in multiple mammalian species and that exogenous GDF11 rapidly activates SMAD signaling and reduces cardiomyocyte size. Unraveling the molecular basis for the age-dependent decline in GDF11/8 could yield insight into age-dependent cardiac pathologies.
Collapse
Affiliation(s)
- Tommaso Poggioli
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Ana Vujic
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Peiguo Yang
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Claudio Macias-Trevino
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Aysu Uygur
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Francesco S Loffredo
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - James R Pancoast
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Miook Cho
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Jill Goldstein
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Rachel M Tandias
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Emilia Gonzalez
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Ryan G Walker
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Thomas B Thompson
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Amy J Wagers
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Yick W Fong
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.)
| | - Richard T Lee
- From the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., M.C., J.G., R.M.T., E.G., A.J.W., Y.W.F., R.T.L.); Brigham Regenerative Medicine Center and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (T.P., A.V., P.Y., C.M.-T., A.U., F.S.L., J.R.P., R.M.T., E.G., Y.W.F., R.T.L.); Department of Molecular Genetics, College of Medicine, University of Cincinnati, OH (R.G.W., T.B.T.); and Howard Hughes Medical Institute, Section on Developmental and Stem Cell Biology, Joslin Diabetes Center, Boston, MA (M.C., J.G., A.J.W.).
| |
Collapse
|
18
|
Loffredo FS, Pancoast JR, Cai L, Vannelli T, Dong JZ, Lee RT, Patwari P. Targeted delivery to cartilage is critical for in vivo efficacy of insulin-like growth factor 1 in a rat model of osteoarthritis. Arthritis Rheumatol 2014; 66:1247-55. [PMID: 24470361 DOI: 10.1002/art.38357] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2013] [Accepted: 01/07/2014] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Acute articular injuries lead to an increased risk of progressive joint damage and osteoarthritis (OA), and no therapies are currently available to repair or protect the injured joint tissue. Intraarticular delivery of therapeutic proteins has been limited by their rapid clearance from the joint space and lack of retention within cartilage. The aim of this study was to test whether targeted delivery to cartilage by fusion with a heparin-binding domain would be sufficient to prolong the in vivo function of the insulin-like growth factor 1 (IGF-1). METHODS We produced a humanized and optimized recombinant HB-IGF-1 fusion protein. By injecting HB-IGF-1, IGF-1, or saline alone into the knee joints of adult Lewis rats, we tested whether fusion with a heparin-binding domain 1) altered the kinetics of retention in joint tissues, 2) prolonged functional stimulation as measured by radiolabel incorporation, and 3) enhanced efficacy in a rat model of surgically induced OA, using weekly injections. RESULTS Fusion of heparin-binding domain with IGF-1 prolonged retention in articular and meniscal cartilage from <1 day to 8 days after injection. Unmodified IGF-1 had no functional effect 2 days after injection, whereas HB-IGF-1 stimulated meniscal cartilage at least 4 days after injection. HB-IGF-1, but not IGF-1, significantly slowed cartilage damage in a rat model of OA. CONCLUSION Heparin-binding domain fusions can transform rapidly cleared proteins into potential intraarticular therapies by targeting them to cartilage.
Collapse
Affiliation(s)
- Francesco S Loffredo
- Brigham and Women's Hospital and Harvard Medical School, Cambridge, Massachusetts
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Age-related diastolic dysfunction is a major factor in the epidemic of heart failure. In patients hospitalized with heart failure, HFpEF is now as common as heart failure with reduced ejection fraction. We now have many successful treatments for heart failure with reduced ejection fraction, while specific treatment options for HFpEF patients remain elusive. The lack of treatments for HFpEF reflects our very incomplete understanding of this constellation of diseases. There are many pathophysiological factors in HFpEF, but aging appears to play an important role. Here, we propose that aging of the myocardium is itself a specific pathophysiological process. New insights into the aging heart, including hormonal controls and specific molecular pathways, such as microRNAs, are pointing to myocardial aging as a potentially reversible process. While the overall process of aging remains mysterious, understanding the molecular pathways of myocardial aging has never been more important. Unraveling these pathways could lead to new therapies for the enormous and growing problem of HFpEF.
Collapse
Affiliation(s)
- Francesco S Loffredo
- From the Department of Stem Cell and Regenerative Biology, Harvard University, Brigham Regenerative Medicine Center, Cambridge, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA; and Harvard Stem Cell Institute, Cambridge, MA
| | - Andriana P Nikolova
- From the Department of Stem Cell and Regenerative Biology, Harvard University, Brigham Regenerative Medicine Center, Cambridge, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA; and Harvard Stem Cell Institute, Cambridge, MA
| | - James R Pancoast
- From the Department of Stem Cell and Regenerative Biology, Harvard University, Brigham Regenerative Medicine Center, Cambridge, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA; and Harvard Stem Cell Institute, Cambridge, MA
| | - Richard T Lee
- From the Department of Stem Cell and Regenerative Biology, Harvard University, Brigham Regenerative Medicine Center, Cambridge, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA; and Harvard Stem Cell Institute, Cambridge, MA.
| |
Collapse
|
20
|
Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, Chen JW, Lee RT, Wagers AJ, Rubin LL. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014; 344:630-4. [PMID: 24797482 PMCID: PMC4123747 DOI: 10.1126/science.1251141] [Citation(s) in RCA: 725] [Impact Index Per Article: 72.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In the adult central nervous system, the vasculature of the neurogenic niche regulates neural stem cell behavior by providing circulating and secreted factors. Age-related decline of neurogenesis and cognitive function is associated with reduced blood flow and decreased numbers of neural stem cells. Therefore, restoring the functionality of the niche should counteract some of the negative effects of aging. We show that factors found in young blood induce vascular remodeling, culminating in increased neurogenesis and improved olfactory discrimination in aging mice. Further, we show that GDF11 alone can improve the cerebral vasculature and enhance neurogenesis. The identification of factors that slow the age-dependent deterioration of the neurogenic niche in mice may constitute the basis for new methods of treating age-related neurodegenerative and neurovascular diseases.
Collapse
Affiliation(s)
- Lida Katsimpardi
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
| | - Nadia K. Litterman
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
| | - Pamela A. Schein
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
| | - Christine M. Miller
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
- Howard Hughes Medical Institute, Joslin Diabetes Center and the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School
| | - Francesco S. Loffredo
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
- Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA
| | - Gregory R. Wojtkiewicz
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School
| | - John W. Chen
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School
| | - Richard T. Lee
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
- Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA
| | - Amy J. Wagers
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
- Howard Hughes Medical Institute, Joslin Diabetes Center and the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School
| | - Lee L. Rubin
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
- Harvard Stem Cell Institute, Cambridge, MA
| |
Collapse
|
21
|
Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, Miller C, Regalado SG, Loffredo FS, Pancoast JR, Hirshman MF, Lebowitz J, Shadrach JL, Cerletti M, Kim MJ, Serwold T, Goodyear LJ, Rosner B, Lee RT, Wagers AJ. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014; 344:649-52. [PMID: 24797481 DOI: 10.1126/science.1251152] [Citation(s) in RCA: 605] [Impact Index Per Article: 60.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Parabiosis experiments indicate that impaired regeneration in aged mice is reversible by exposure to a young circulation, suggesting that young blood contains humoral "rejuvenating" factors that can restore regenerative function. Here, we demonstrate that the circulating protein growth differentiation factor 11 (GDF11) is a rejuvenating factor for skeletal muscle. Supplementation of systemic GDF11 levels, which normally decline with age, by heterochronic parabiosis or systemic delivery of recombinant protein, reversed functional impairments and restored genomic integrity in aged muscle stem cells (satellite cells). Increased GDF11 levels in aged mice also improved muscle structural and functional features and increased strength and endurance exercise capacity. These data indicate that GDF11 systemically regulates muscle aging and may be therapeutically useful for reversing age-related skeletal muscle and stem cell dysfunction.
Collapse
Affiliation(s)
- Manisha Sinha
- Harvard Stem Cell Institute and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Aging is a major factor in many cardiovascular diseases. The molecular factors that regulate age-related changes in cardiac physiology and contribute to the increased cardiovascular risk in the elderly are not fully understood. A study recently published in Nature suggests a specific role for microRNAs (miRNAs) in regulating cardiac aging and function, challenging the concept that aging is an inevitable process in the heart.
Collapse
Affiliation(s)
- Francesco S Loffredo
- Harvard Stem Cell Institute, The Brigham Regenerative Medicine Center, Brigham and Women's Hospital, Boston, MA, USA
| | | | | |
Collapse
|
23
|
Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, Sinha M, Dall'Osso C, Khong D, Shadrach JL, Miller CM, Singer BS, Stewart A, Psychogios N, Gerszten RE, Hartigan AJ, Kim MJ, Serwold T, Wagers AJ, Lee RT. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013; 153:828-39. [PMID: 23663781 DOI: 10.1016/j.cell.2013.04.015] [Citation(s) in RCA: 693] [Impact Index Per Article: 63.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Revised: 02/21/2013] [Accepted: 04/03/2013] [Indexed: 02/06/2023]
Abstract
The most common form of heart failure occurs with normal systolic function and often involves cardiac hypertrophy in the elderly. To clarify the biological mechanisms that drive cardiac hypertrophy in aging, we tested the influence of circulating factors using heterochronic parabiosis, a surgical technique in which joining of animals of different ages leads to a shared circulation. After 4 weeks of exposure to the circulation of young mice, cardiac hypertrophy in old mice dramatically regressed, accompanied by reduced cardiomyocyte size and molecular remodeling. Reversal of age-related hypertrophy was not attributable to hemodynamic or behavioral effects of parabiosis, implicating a blood-borne factor. Using modified aptamer-based proteomics, we identified the TGF-β superfamily member GDF11 as a circulating factor in young mice that declines with age. Treatment of old mice to restore GDF11 to youthful levels recapitulated the effects of parabiosis and reversed age-related hypertrophy, revealing a therapeutic opportunity for cardiac aging.
Collapse
Affiliation(s)
- Francesco S Loffredo
- Harvard Stem Cell Institute, Brigham and Women's Hospital, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|